Table of Contents

• 1. Authorship
• 2. Originality, plagiarism, and duplicate publication
• 3. Secondary publication
• 4. Conflict-of-interest statement
• 5. Statement of human and animal right
• 6. Statement of informed consent and Institutional Review Board approval
• 7. Registration of the clinical trial research
• 8. Process for managing research and publication misconduct
• 9. Process for handling cases requiring corrections, retractions, and editorial expressions of concern
• 10. Editorial responsibilities

For the policies on the research and publication ethics not stated in this instruction, “Good Publication Practice Guidelines for Medical Journals (http://kamje.or.kr)” or “COPE Core Practices (https://publicationethics.org/corepractices)”can be applied.

1. Authorship

It is important to understand that authorship credit should be based on (1) substantial contributions to conceptionand design, acquisition of data, and/or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; (3) final approval of the version to be published; and (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Every author should meet all of these four conditions for every submitted manuscript to J Rhinol. All other persons who have made substantial contributions to the work reported in this manuscript (e.g., data collection, analysis, or writing or editing assistance) but who do not fulfill the authorship criteria should be named with their specific contributions and affiliations in an Acknowledgmentin the manuscript. Written permission to include the names of individuals in the Acknowledgment sectionmust be obtained.

After the initial submission of a manuscript, any changes whatsoever in authorship (adding author(s), deleting author(s), or re-arranging the order of authors) must be explained in writing to the editor in a letter or email from all authors. This letter must be signed by all authors of the paper. Copyright assignment must also be completed by every author.

Correction of authorship: J Rhinol does not correct authorship after publication unless a mistake has been made by the editorial staff. Authorship may be changed before publication but after submission when an authorshipcorrection is requested by all of the authors involved with the manuscript.

Corresponding author(s): The corresponding author(s) is(are) the one individual(s) who take(s) primary responsibility for communication with the journal during the manuscript submission, peer review, and publication process, and typically ensures that all the journal’s administrative requirements, such as providing details of authorship,ethics committee approval, clinical trial registration documentation, and gathering conflict of interest forms and statements, are properly completed, although these duties may be delegated to one or more coauthors. The corresponding author(s) should be available throughout the submission and peer review process to respond to editorial queries in a timely way, and should be available after publication to respond to critiques of the work and cooperate with any requests from the journal for data or additional information should questions about the paper arise after publication [http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html].

2. Originality, plagiarism, and duplicate publication

Submitted manuscripts must not have been previously published in any context, or be under consideration for publication elsewhere. No part of the accepted manuscript should be duplicated in any other scientific journal without the express written permission of the Editorial Board. This restriction does not apply to abstracts or press reports published in connection with scientific meetings.

Submitted manuscripts are screened for possible plagiarism or duplicate publication by the use of Similarity Check upon arrival. If plagiarism or duplicate publication related to the papers of this journal is detected, the manuscripts may be rejected, and their institutions will be informed of this situation. There will also be penaltiesthat will be assessed and applied for the authors if this incident occurs.

A letter of permission is required for any and all copyrighted materials that has been published previously. It is the responsibility of the author to request permission from the publisher for any material that is being reproducedor considered for reproduction by J Rhinol. This requirement applies to text, figures, and tables.

3. Secondary publication

It is possible to republish manuscripts if the manuscripts satisfy the conditions of secondary publication of the ICMJE Recommendations (http://www.icmje.org/urm_main.html).

4. Conflict-of-interest statement

A conflict of interest may exist when an author (or the author’s institution or employer) has financial or personalrelationships that could inappropriately influence (or bias) the author’s decisions, work, or manuscript.

Corresponding author of an article is asked to let the Editor-in-Chief know potential conflict of interest possiblyinfluencing their interpretation of data. Potential conflict of interest is applied even when the authors are confidentthat their judgments have not been influenced in the manuscript. Such conflicts may be financial supports or connections to pharmaceutical companies, political pressure from interest groups, or academic problems.

The Editor-in-Chief will decide whether the information of the conflict should be included in the published paper.Before publishing such information, the Editor-in-Chief will consult with the corresponding author. In particular,all sources of funding for a research should be explicitly stated.

5. Statement of human and animal right

Clinical research should be done in accordance of the “Ethical Principles for Medical Research Involving HumanSubjects,” outlined in the Helsinki Declaration. Clinical studies that do not meet the Helsinki Declaration will not be considered for use in the publication. Human subjects should not be identifiable, such that the confidentialityof the patient’s names, initials, hospital numbers, dates of birth, or other protected healthcare informationshould not be disclosed. For animal subjects, research should be performed based on the National or Institutional Guide for the Care and Use of Laboratory Animals, and the ethical treatment of all experimental animals should be maintained.

6. Statement of informed consent and Institutional Review Board approval

Copies of written informed consents should be kept for studies on human subjects. For the clinical studies with human subjects, there should be a certificate, an agreement, or the approval by the Institutional Review Board(IRB) of the author’s affiliated institution. If necessary, the editor or reviewers may request copies of these documentsto resolve any questions regarding IRB approval and study conduct.

7. Registration of the clinical trial research

Any research that deals with a clinical trial should be registered with the primary national clinical trial registry site such as the Korea Clinical Research Information Service (CRIS, http://cris.nih.go.kr), other primary national registry sites accredited by the World Health Organization (https://www.who.int/clinical-trials-registry-platform/network/primary-registries) or ClinicalTrials.gov (http://clinicaltrials.gov/), a service of the United States National Institutes of Health.

8. Process for managing research and publication misconduct

When the journal faces suspected cases of research and publication misconduct such as redundant (duplicate) publication, plagiarism, fraudulent or fabricated data, changes in authorship, an undisclosed conflict of interest, ethical problems with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaintsagainst editors, and so on, the resolution process will be completed following the procedures outlined in the flowchart provided by the COPE (http://publicationethics.org/resources/flowcharts). The discussion and decisionon the suspected cases will be carried out by the Editorial Board.

9. Process for handling cases requiring corrections, retractions, and editorial expressions of concern

Cases that require editorial expressions of concern or retraction shall follow the COPE flowcharts (http://publicationethics.org/resources/flowcharts). If a correction is required, the procedure to provide the correction will follow the ICMJE Recommendation (http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/corrections-and-version-control.html).

10. Editorial responsibilities

The Editorial Board will continuously work to monitor and safeguard publication ethics: guidelines for retractingarticles; maintenance of the integrity of the academic record; preclusion of business needs from compromising intellectual and ethical standards; publishing corrections, clarifications, retractions, and apologies when needed; and excluding plagiarism and fraudulent data. The editors maintain the following responsibilities: responsibility and authority to reject and accept articles; avoiding any conflict of interest with respect to articles they reject or accept; promoting publication of corrections or retractions when errors are found; and the preservation of the anonymity of reviewers.